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Despite the discovery of the cystic ﬁbrosis (CF) gene in 1989, there are no
approved therapies that target the underlying defect in the CF gene product, the
CF transmembrane conductance regulator (CFTR). Ninety percent of CF patients
carry the F508del CFTR mutation that leads to defects in CFTR protein folding,
preventing it from reaching the cell surface where it normally regulates salt transport
and water movement across epithelial cells. Here, we describe the pharmacology
of VX-809, an investigational small molecule CFTR corrector that increased the
cell surface density of F508del-CFTR in vitro. In these studies, we show that VX-
809 increased the amount of properly folded CFTR that was able to exit from the
endoplasmic reticulum and, as a result, increased anion transport across human
CF airway cell cultures carrying the F508del-CFTR mutation on both alleles from
3% to approximately 15% of values observed in non-CF airway. This increase was
sufﬁcient to augment ﬂuid secretion from these airway cultures, which could be
further improved by the addition of VX-770, a CFTR potentiator. These in vitro
studies suggest that small molecule drugs such as VX-809, either alone or in
combination, may directly address the underlying genetic defect in CF to restore
CFTR function.
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Cystic ﬁbrosis (CF) is caused by mutations in the CF transmembrane conductor
(CFTR) gene, which encodes a PKA-activated anion channel. Increasing Cl− ion
ﬂow through cell-surface CFTR is a potential therapeutic approach in CF. Previous
in vitro studies showed that the investigational CFTR potentiator, VX-770, increased
the gating activity of the G551D (class III gating mutation) and F508del (class II
trafﬁcking mutation) forms of CFTR. This in vitro study aimed to evaluate if VX-
770 can potentiate the activity of other CFTR mutant forms. We measured the
effect of VX-770 on CFTR-mediated Cl− transport in recombinant cells expressing
the 50 most common missense and deletion CFTR mutations. Class III mutations
demonstrated the largest VX-770 response, with all 8 class III mutations tested (e.g.,
G178R, G551D, G551S, G1349D) showing a >10-fold increase in Cl− transport
compared to baseline. VX-770 also potentiated, albeit to a lesser extent, class IV
(conductance) mutations (e.g., R117H, D1152H, I148T), class II mutations that
result in a small amount of CFTR trafﬁcking to the cell surface (e.g., F508del,
S549R), and multiple unclassiﬁed CFTR mutant forms. For the majority of class
II mutations other than F508del and S549R, no response to VX-770 was observed
in the absence of compounds that correct defective CFTR trafﬁcking. VX-770 also
increased Cl− transport in cultured human bronchial epithelia from CF patients
carrying the F508del mutation and a class V (reduced synthesis; e.g., 2789+5G>A,
3272−26A>AG) mutation on the other allele. These in vitro data support the
rationale for evaluating VX-770 monotherapy in CF patients carrying a variety
of CFTR mutant forms.
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In the last years, several small molecules were identiﬁed by high throughput
screening that could restore mutated CFTR function. Compounds addressing CFTR
gating defects are referred to as potentiators. The basolateral K+ channel KCa3.1
has been documented to play a prominent role in establishing a suitable driving force
for CFTR-mediated Cl− secretion in airway epithelial cells. Thus, a research aimed
at identifying structural parameters by which CFTR potentiators can simultaneously
activate both CFTR and KCa3.1 offers new perspectives to the correction of ion
transport defects in CF epithelia. Patch clamp measurements, computer modeling
and site directed mutagenesis approaches were thus used to characterize the molec-
ular determinants underlying the action of CBIQ a CFTR potentiator documented
to also activate KCa3.1. Our results show that CBIQ destabilizes a non conducting
state of the channel by binding to a site accessible irrespectively of the channel
conducting state. Experiments carried with the constitutively active A279G mutant
also conﬁrmed that Ca2+ is absolutely required to the action of CBIQ. Experiments
in which Ba2+ was used as a probe were ﬁnally performed to determine if the action
of CBIQ involves an effect on the selectivity ﬁlter. Our results showed that Ba2+
can displace CBIQ from its activity site, suggesting that the increases in channel
activity induced by CBIQ could result from a change in the energetic of the channel
at the level of the selectivity ﬁlter. On the basis of our results, we conclude that
CBIQ, a CFTR potentiator, can activate KCa3.1 by binding to a hydrophobic pocket
connected to the channel selectivity ﬁlter region.
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CFTR is composed of two transmembrane domains, two nucleotide domains and
a regulatory domain. In the kidney a truncated splice variant of CFTR is present
with 145 bases pairs deleted that results in a frame shift and a premature stop
codon leading to a new protein that includes only the ﬁrst half of CFTR called
TNR CFTR. The purpose of this study is to understand the trafﬁcking, processing
of TNR and why the kidney is not involved in Cystic Fibrosis.
TNR is easily detectable as two distinct bands. When cells were transfected with
TNR and treated for 16 hours with proteasome inhibitors, the protein expression
was not signiﬁcantly changed. A similar response was also observed with lysosomal
inhibitors. These data suggest that TNR protein is not recognized by the cell’s quality
control mechanism as a mutant protein. To evaluate the rate of degradation cells
were treated with cycloheximide. The results showed that TNR protein has a similar
time course of degradation compared to wt CFTR. Surface biotinylation studies
show that only a small fraction of TNR resides at the plasma membrane. Also TNR
cannot act to transcomplement DF508 CFTR in contrast to other truncated CFTR
such as D264 which is missing the N-terminal portions of CFTR. Consistent with
these data is that small molecule correctors such as 4A and VRT325 which do
promote DF508 CFTR trafﬁcking out of the ER do not affect TNR CFTR. Our
data suggest that TNR is a very stable protein, the majority of which resides within
the ER. This can be compared to D264 and DF508 CFTR both are recognized as
mutant proteins and rapidly degraded.
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